Magnitudes of Risk Factors of Venous Thromboembolism and Quality of Anticoagulant Therapy in Ethiopia: A Systematic Review
Bekalu Kebede,Tirsit Ketsela
DOI: https://doi.org/10.2147/VHRM.S347667
2022-04-12
Vascular Health and Risk Management
Abstract:Bekalu Kebede, Tirsit Ketsela Clinical Pharmacy Unit, Pharmacy Department, Health Science College, Debre Markos University, Debre Markos, Ethiopia Correspondence: Bekalu Kebede, Department of Pharmacy, College of Health Sciences, Debre Markos University, P.O. Box 269, Debre Markos, Ethiopia, Tel +251 921286140, Email Background: Venous thromboembolism is one of the major public health problems in the world. Though several studies were conducted to estimate common risk factors of venous thromboembolism and quality of anticoagulant therapy in Ethiopia, it is difficult to estimate the overall burdens of risk factors and quality of anticoagulant use because of the lack of a nationwide study. Objective: To assess magnitudes of risk factors of venous thromboembolism and quality of anticoagulant therapy in Ethiopia. Materials and Methods: Electronic searching using PubMed, EMBASE, Science Direct, Cochrane Database, Scopus, Hinari, Sci-Hub, African Journals Online Library, and Free-text Web Searches using Google Scholar was conducted from September, 15 to October 27, 2021. Each of the original studies was identified by Mesh terms and Boolean search technique using full title, various keywords and was assessed using the Joanna Briggs Institute Critical Appraisal Checklist. The data were extracted using a format prepared in Microsoft Excel and exported to STATA 14.0 for the outcome analyses. Results: The database search delivered a total of 2118 studies. After articles were removed by duplications, titles, reading the abstract, and assessed for eligibility criteria, 12 articles were found suitable for the systematic review. Prolonged immobilization (41.30%) was the most commonly observed risk factor of venous thrombosis followed by acute infection (40.25%). The proportion of therapeutic range (INR = 2– 3), sub-therapeutic range (INR 3) were 32.15%, 47.58%, and 17.62%, respectively. One hundred and thirty-eight patients (11.4%) have developed minor or major bleeding complications. Conclusion: Prolonged immobilization and acute infection were the main risk factors for venous thromboembolism. The quality of anticoagulant therapy in Ethiopia was poor and bleeding complications were high. A strong effort is needed to improve the quality of anticoagulation and close monitoring of patients' international normalized ratio is required to improve treatment outcomes. Keywords: anticoagulant, risk assessment, thrombosis, risk factors, venous thromboembolism, Ethiopia Venous thromboembolic diseases (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of morbidity and mortality in the world. 1,2 It is a serious condition with an incidence of 10% to 30% of people dying within 1 month of diagnosis and one-half of them have long-term complications. 3–5 It is also associated with significant cardiac and pulmonary complications such as hypoxemias, increased pulmonary vascular resistance (pulmonary hypertension) leading to right heart failure, and bleeding. 6–9 Including Ethiopia, VTE is common in developing countries. 10–12 Mortality rate is high, hospitalizations are frequent and associated with worse outcomes with high use healthcare cost. 11 Moreover, in developing countries priority, is given to acute disorders, child and maternal health care, and control of communicable diseases; with little emphasis on non-communicable diseases. 2,4 Advanced age, malignancy, trauma, post-surgery, obesity, chronic disease, pregnancy, oral contraceptive, long-term immobilization, and HIV infection are the most common risk factors for VTE reported from different studies. 6,9,10 Anticoagulation therapies remain the mainstay of VTE treatment, DVT and PE are treated similarly. 11 International clinical practice guidelines such as American college chest physicians' treatment guidelines recommended that injectable anticoagulation should overlap with warfarin therapy for at least 5 days and until an international normalized ratio (INR) ≥2 for at least 24 hours. 12 This guideline also emphasizes that unfractionated heparin (UFH) should be weight-based dosing, subcutaneously (initial dose 333 units/kg followed by 250 units/kg twice daily) and intravenous dose (80–100 units/kg loading dose; followed by 18–20 units/kg/hour initial infusion rate). The dose of warfarin should be periodically adjusted to achieve and maintain an INR between 2 and 3 with a duration of treatment of 3 months or longer. These guideline-based treatment approaches were significantly associated with lower death, stroke/coronary heart diseases (CHD), and acute kidney injury (AKI). 13 However, these -Abstract Truncated-